Nasal Polyps Treatment Market Report 2025

This Nasal Polyps Treatment report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The nasal polyps treatment market size has grown strongly in recent years. It will grow from $5.27 billion in 2024 to $5.7 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to surgical procedures, steroid medications, allergic rhinitis, chronic sinusitis, environmental factors.

The nasal polyps treatment market size is expected to see strong growth in the next few years. It will grow to $8.22 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to drug development, personalized medicine, telehealth services, patient-centric care, regulatory approvals. Major trends in the forecast period include diagnostic technologies, medical advancements, biologic therapies, immunotherapies, collaborative research.

Increasing healthcare expenditure is anticipated to propel the growth of the nasal polyps treatment market. Healthcare expenditure refers to the total financial resources utilized by individuals, governments, and organizations within a healthcare system to cover costs associated with medical services, treatments, medications, and healthcare infrastructure. As healthcare budgets grow, more resources are likely to be allocated for the diagnosis, management, and treatment of nasal polyps. This financial investment can enhance patient access to advanced therapies, innovative treatment options, and increased research and development, ultimately driving market expansion. For example, in December 2023, data from the Centers for Medicare & Medicaid Services, a US-based federal agency, revealed that U.S. healthcare spending rose by 4.1%, reaching $4.5 trillion in 2022, surpassing the 3.2% growth recorded in 2021. Thus, the rising healthcare expenditure is fostering growth in the nasal polyps treatment market.

The increasing aging population is projected to drive the growth of the nasal polyps treatment market in the coming years. An aging population refers to a demographic shift marked by a higher percentage of elderly individuals (typically aged 65 and older) compared to younger age groups within a given population. As people age, they become more prone to nasal polyps, which are frequently seen in older adults. For example, in October 2024, data published by the World Health Organization, a United Nations agency based in Switzerland, indicated that the global population aged 60 and over is expected to grow from 1 billion in 2020 to 1.4 billion by 2030 and double to 2.1 billion by 2050, representing one in six people worldwide. Consequently, the rising aging population is set to boost the nasal polyps treatment market.

New product innovation is a significant trend gaining traction in the treatment of nasal polyps. Leading companies in the nasal polyps treatment market are emphasizing new product developments to enhance their market presence. For example, in September 2024, AstraZeneca, a UK-based pharmaceutical firm, announced that the U.S. Food and Drug Administration (FDA) had approved Fasenra (benralizumab). This drug represents a considerable advancement in treating eosinophilic granulomatosis with polyangiitis (EGPA), achieving nearly 60% remission among patients and allowing 41% to completely discontinue oral corticosteroids, thereby minimizing long-term side effects associated with steroids. This approval broadens treatment options for approximately 15,000 patients in the U.S. with EGPA, a condition frequently linked to debilitating nasal and sinus symptoms, further highlighting the demand for effective therapies in managing eosinophilic diseases.

Major companies in the Nasal Polyps Treatment market are actively pursuing Food and Drug Administration (FDA) approvals to introduce new therapies. FDA approvals refer to the regulatory procedures through which the U.S. FDA assesses and authorizes the marketing and distribution of drugs, medical devices, and food products, ensuring their safety and effectiveness for public use. For example, in September 2024, Regeneron Pharmaceuticals, Inc., a U.S.-based biopharmaceutical company, along with Sanofi SA, a pharmaceutical and healthcare company based in France, announced the approval of Dupixent (dupilumab) as an add-on maintenance treatment for adolescents aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) by the U.S. Food and Drug Administration (FDA). This approval designates it as the first and only biologic treatment specifically indicated for this age group. It addresses the unmet medical needs of around 9,000 adolescents in the U.S. suffering from CRSwNP, providing a new option that alleviates symptoms, decreases nasal polyp recurrence, and improves overall quality of life.

In May 2022, Medtronic plc, a medical device company based in Ireland, acquired Intersect ENT for $1.1 billion. This acquisition is designed to enhance its ear, nose, and throat (ENT) portfolio by integrating innovative bioabsorbable steroid-eluting sinus implants, which aim to improve post-operative outcomes and meet the treatment needs of patients with chronic rhinosinusitis and nasal polyps. Intersect ENT is a U.S.-based medical technology firm that produces drug delivery devices for ear, nose, and throat (ENT) applications, including treatments for nasal polyps.

Major companies operating in the nasal polyps treatment market include Sanofi SA, GlaxoSmithKline plc, F. Hoffmann La Roche AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Cipla Ltd., Circassia Pharmaceuticals plc, Dr. Reddy's Laboratories Ltd., Genentech Inc., Glenmark Pharmaceuticals Ltd., Johnson & Johnson Services Inc., Lupin Limited, Meda AB, Novartis AG, Optinose US Inc., Orion Corporation, Pfizer Inc., Regeneron Ireland DAC, Regeneron Pharmaceuticals Inc., Sandoz International GmbH, Stallergenes Greer plc, Sun Pharmaceutical Industries Ltd., Vectura Group plc, Zydus Cadila Ltd.

North America was the largest region in the nasal polyps treatment market in 2024 Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nasal polyps treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the nasal polyps treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.

Nasal polyps are soft, painless, noncancerous growths on the lining of nasal passages or sinuses. They often dangle like grapes or teardrops and are associated with conditions such as asthma, persistent infections, allergies, medication sensitivity, and other immunological disorders.

The nasal polyps treatment market involves the sales of treatments used for nasal polyps. These treatments aim to shrink or repair nasal polyps. Nasal polyps can have connections to various health issues, including asthma, persistent infections, allergies, medication sensitivity, and other immunological disorders. The market includes entities such as organizations, sole traders, and partnerships that provide products or services related to the treatment of nasal polyps.

The nasal polyps treatment market research report is one of a series of new reports that provides nasal polyps treatment market statistics, including nasal polyps treatment industry global market size, regional shares, competitors with a nasal polyps treatment market share, detailed nasal polyps treatment market segments, market trends and opportunities, and any further data you may need to thrive in the nasal polyps treatment industry. This nasal polyps treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nasal polyps treatment market includes revenues earned by entities by nasal corticosteroids, oral and injectable corticosteroids, and other medications. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.